# Prevalence and impact of molecular variation in the three-prime repair exonuclease 1 TREX1 and its implications for oncology

## TL;DR

This paper explores how variations in the TREX1 gene affect cancer outcomes and immune responses, revealing new insights into its role in oncology.

## Contribution

The study integrates TREX1 sequence data across species and cancer samples to reveal novel implications of TREX1 molecular variation in cancer.

## Key findings

- TREX1b is conserved in placental mammals but has unique C-terminal regions in egg-laying mammals and marsupials.
- TREX1 variants in cancer and autoimmune diseases may impact protein stability and function.
- TREX1 gene deletion in tumors correlates with poor patient outcomes, likely due to co-occurring 3p chromosomal loss.

## Abstract

The three-prime repair exonuclease 1, TREX1, degrades cytosolic DNA to prevent aberrant immune activation. Its inactivation results in DNA accumulation in the cytosol and induction of the cGAS-STING DNA sensing pathway, interferon signaling, and inflammation. Germline pathogenic TREX1 mutations are known to lead to hereditary autoimmune and autoinflammatory disorders, whereas the consequences of TREX1 mutations in cancer remain poorly understood.

To assess the importance of human TREX1 amino acid variants, we analyzed protein sequences of the functional TREX1b isoform from 168 mammalian species and integrated available data on TREX1 sequence and copy number alterations in hereditary autoimmune and autoinflammatory disorders, cancer, and in human populations. While the entire TREX1b protein was conserved in placental mammals, egg-laying mammals and marsupials had their own unique C-terminal regions, with each predicted to contain a transmembrane domain. We modeled human TREX1 variants occurring in autoimmune disease and cancer samples at 12 protein positions to evaluate their predicted impact on protein stability and function.

Our findings provide novel insight into the role of TREX1 molecular variation in cancer, where genetic or epigenetic loss of TREX1 activity may improve susceptibility to treatment. However, TREX1 gene deletion in tumors was associated with unfavorable patient outcomes, most likely due its frequent co-occurrence with the loss of the entire 3p chromosomal arm, which contains known cancer-related genes.

The online version contains supplementary material available at 10.1186/s40246-025-00785-y.